AI Article Synopsis

  • The study addresses the challenge of ensuring consistency in metabolomics measurements across different laboratories by using a standardized protocol with the Biocrates AbsoluteIDQ p400HR kit to analyze various blood specimens.
  • Approximately 250 metabolites were reliably quantified using Orbitrap instruments, revealing varying interlaboratory variance across different metabolite classes, with a median bias of <50% from reference values for nearly 80% of analytes tested.
  • The authors recommend best practices for quality control, system suitability, and calibration, highlighting that with proper controls, high-resolution metabolomics can produce accurate and comparable results across labs.

Article Abstract

A challenge facing metabolomics in the analysis of large human cohorts is the cross-laboratory comparability of quantitative metabolomics measurements. In this study, 14 laboratories analyzed various blood specimens using a common experimental protocol provided with the Biocrates AbsoluteIDQ p400HR kit, to quantify up to 408 metabolites. The specimens included human plasma and serum from male and female donors, mouse and rat plasma, as well as NIST SRM 1950 reference plasma. The metabolite classes covered range from polar (e.g., amino acids and biogenic amines) to nonpolar (e.g., diacyl- and triacyl-glycerols), and they span 11 common metabolite classes. The manuscript describes a strict system suitability testing (SST) criteria used to evaluate each laboratory's readiness to perform the assay, and provides the SST Skyline documents for public dissemination. The study found approximately 250 metabolites were routinely quantified in the sample types tested, using Orbitrap instruments. Interlaboratory variance for the NIST SRM-1950 has a median of 10% for amino acids, 24% for biogenic amines, 38% for acylcarnitines, 25% for glycerolipids, 23% for glycerophospholipids, 16% for cholesteryl esters, 15% for sphingolipids, and 9% for hexoses. Comparing to consensus values for NIST SRM-1950, nearly 80% of comparable analytes demonstrated bias of <50% from the reference value. The findings of this study result in recommendations of best practices for system suitability, quality control, and calibration. We demonstrate that with appropriate controls, high-resolution metabolomics can provide accurate results with good precision across laboratories, and the p400HR therefore is a reliable approach for generating consistent and comparable metabolomics data.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310668PMC
http://dx.doi.org/10.1021/acs.analchem.9b02908DOI Listing

Publication Analysis

Top Keywords

metabolite classes
8
amino acids
8
biogenic amines
8
nist srm-1950
8
international ring
4
ring trial
4
trial high
4
high resolution
4
resolution targeted
4
targeted metabolomics
4

Similar Publications

Discovery of a Chimeric Polyketide Family as Cancer Immunogenic Chemotherapeutic Leads.

J Am Chem Soc

December 2024

Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina 29208, United States.

Discovery of cancer immunogenic chemotherapeutics represents an emerging, highly promising direction for cancer treatment that uses a chemical drug to achieve the efficacy of both chemotherapy and immunotherapy. Herein, we report a high-throughput screening platform and the subsequent discovery of a new class of cancer immunogenic chemotherapeutic leads. Our platform integrates informatics-based activity metabolomics for the rapid identification of microbial natural products with both novel structures and potent activities.

View Article and Find Full Text PDF

Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis.

Mult Scler Relat Disord

December 2024

Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic.

Background: Fingolimod is a first-in-class, orally administered drug indicated for the treatment of relapsing-remitting multiple sclerosis. It acts as an immunomodulator, is classified as a "disease-modifying therapy", and its main mechanism of action is the modulation of sphingosine-1-phosphate receptors. In this prospective pilot study, whole blood concentrations of fingolimod and fingolimod phosphate obtained during routine health care were measured.

View Article and Find Full Text PDF

Targeted isolation of diketopiperazines from a deep-sea derived fungus with anti-neuroinflammatory effects.

Bioorg Chem

December 2024

State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, PR China; Ningbo Institute of Marine Medicine, Peking University, Beijing 100191, PR China. Electronic address:

Prenylated indole diketopiperazines represent a diverse array of alkaloids with complex chemical scaffolds and with a wide range of biological activities. Aiming to discover bioactive metabolites with structural novelty, genomic annotation in association with the MS/MS-based molecular networking demonstrated a deep-sea derived fungus Aspergillus puulaauensis F77 containing a profile of diketopiperazines. Targeted separation of the cultured fungus led to the isolation of 19 undescribed austamide-type diketopiperazines namely versicoines A-S.

View Article and Find Full Text PDF

Introduction: Tree bacterial diseases are a threat in forestry due to their increasing incidence and severity. Understanding tree defence mechanisms requires evaluating metabolic changes arising during infection. Metabolite extraction affects the chemical diversity of the samples and, therefore, the biological relevance of the data.

View Article and Find Full Text PDF

Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in .

Metabolites

December 2024

Pharmacognosy and Pharmaceutical Chemistry Department, Faculty of Pharmacy, Taibah University, Al Madinah Al Munawarah 30001, Saudi Arabia.

is a highly multidrug-resistant pathogen resistant to almost all classes of antibiotics; new therapeutic strategies against this infectious agent are urgently needed. Shikimate kinase is an enzyme belonging to the shikimate pathway and has become a potential target for drug development. This work describes the search for Food and Drug Administration (FDA)-approved drugs and natural compounds, including gallic acid, that could be repurposed as selective shikimate kinase inhibitors by integrated computational and experimental approaches.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!